Participants
Eligible participants were between 5-21 years old with newly diagnosed
ALL (B- or T-cell) and fluent in English or Spanish. All participants
were enrolled within three days of starting induction therapy. Consent
and assent, when applicable, were obtained from parents and
participants. Participants were removed from the study if they relapsed,
deceased, or left the institution.